US Copaxone patents confirmed as invalid
Four patents protecting Teva’s Copaxone (glatiramer acetate) 40mg/ ml thrice-weekly formulation are invalid as obvious, the US Court of Appeals has confirmed in two parallel decisions. The decisions remove the threat of damages against Mylan and Sandoz, which launched glatiramer acetate (GA) 40mg pre-filled syringes ‘at risk’ pending Teva’s appeal (Generics bulletin, 16 February 2018, page 15).
You may also be interested in...
A mixed verdict in Canadian litigation involving Pharmascience has seen one patent protecting Teva’s Copaxone 40mg upheld and one deemed invalid. Pharmascience plans to appeal.
Mylan has celebrated a reversal from the European Patent Office that has seen a key patent protecting Teva’s higher-strength 40mg/ml thrice-weekly version of Copaxone deemed invalid and revoked across Europe. Meanwhile, Teva has commented on the possibility of an appeal.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.